This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Resources

Ophthalmology Resources

Learn more about EYLEA® (aflibercept) 8 mg

Ophthalmology Resources Banner

Access the latest resources below to gain further insights into EYLEA® (aflibercept) 8 mg and to support your prescribing decisions.

 

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).

Clinical value model

Clinical Value Model

 Discover how EYLEA 8 mg impacts capacity and resources for informed decision-making.

Arrange a Session
Consensus pathways

Optimising Treatment Pathways

Explore expert consensus on EYLEA 8 mg for nAMD and DMO management.

Download Here
Formulary Guide

Updated Formulary Guide

Access guidance on clinical equivalence and NHS pricing for EYLEA 8 mg.

Download Here
Costed Integrated Patient Scenario (CIPS) report

Costed Integrated Patient Scenario (CIPS) Report

Learn about the economic benefits of optimal care pathways.

Download Full Report
State of the Nation (SotN) Report

State of the Nation (SotN) Report

Insights into current ophthalmology care for patients at risk of vision loss.

Coming Soon

Abbreviations

DMO, diabetic macular oedema. HCP, healthcare professional. nAMD, neovascular (wet) age-related macular degeneration.

Prescribing information for EYLEA® (aflibercept)

can be found here
.

EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2911, July 2025
Real World Experience
Practical insights into the experiences of clinicians implementing treatment with EYLEA® (aflibercept) 8 mg in the UK
PP-EYL-GB-3012, October 2025
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025

PP-EYL-GB-2954 | September 2025